These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 16029450)

  • 1. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
    Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
    Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.
    Bruenke J; Fischer B; Barbin K; Schreiter K; Wachter Y; Mahr K; Titgemeyer F; Niederweis M; Peipp M; Zunino SJ; Repp R; Valerius T; Fey GH
    Br J Haematol; 2004 Apr; 125(2):167-79. PubMed ID: 15059139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
    Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
    J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells.
    Kellner C; Bruenke J; Horner H; Schubert J; Schwenkert M; Mentz K; Barbin K; Stein C; Peipp M; Stockmeyer B; Fey GH
    Cancer Lett; 2011 Apr; 303(2):128-39. PubMed ID: 21339041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
    Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
    J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.
    Singer H; Kellner C; Lanig H; Aigner M; Stockmeyer B; Oduncu F; Schwemmlein M; Stein C; Mentz K; Mackensen A; Fey GH
    J Immunother; 2010; 33(6):599-608. PubMed ID: 20551837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.
    Johnson S; Burke S; Huang L; Gorlatov S; Li H; Wang W; Zhang W; Tuaillon N; Rainey J; Barat B; Yang Y; Jin L; Ciccarone V; Moore PA; Koenig S; Bonvini E
    J Mol Biol; 2010 Jun; 399(3):436-49. PubMed ID: 20382161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
    Würflein D; Dechant M; Stockmeyer B; Tutt AL; Hu P; Repp R; Kalden JR; van de Winkel JG; Epstein AL; Valerius T; Glennie M; Gramatzki M
    Cancer Res; 1998 Jul; 58(14):3051-8. PubMed ID: 9679970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting.
    Schubert I; Kellner C; Stein C; Kügler M; Schwenkert M; Saul D; Stockmeyer B; Berens C; Oduncu FS; Mackensen A; Fey GH
    MAbs; 2012; 4(1):45-56. PubMed ID: 22327429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
    Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
    J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
    Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M
    Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
    Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
    Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.
    Kügler M; Stein C; Kellner C; Mentz K; Saul D; Schwenkert M; Schubert I; Singer H; Oduncu F; Stockmeyer B; Mackensen A; Fey GH
    Br J Haematol; 2010 Sep; 150(5):574-86. PubMed ID: 20636437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
    Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB
    Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma.
    Kipriyanov SM; Cochlovius B; Schäfer HJ; Moldenhauer G; Bähre A; Le Gall F; Knackmuss S; Little M
    J Immunol; 2002 Jul; 169(1):137-44. PubMed ID: 12077238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional humanization of an anti-CD16 Fab fragment: obstacles of switching from murine {lambda} to human {lambda} or {kappa} light chains.
    Schlapschy M; Fogarasi M; Gruber H; Gresch O; Schäfer C; Aguib Y; Skerra A
    Protein Eng Des Sel; 2009 Mar; 22(3):175-88. PubMed ID: 19022801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.
    de Romeuf C; Dutertre CA; Le Garff-Tavernier M; Fournier N; Gaucher C; Glacet A; Jorieux S; Bihoreau N; Behrens CK; Béliard R; Vieillard V; Cazin B; Bourel D; Prost JF; Teillaud JL; Merle-Béral H
    Br J Haematol; 2008 Mar; 140(6):635-43. PubMed ID: 18302712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
    Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
    J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
    Löffler A; Gruen M; Wuchter C; Schriever F; Kufer P; Dreier T; Hanakam F; Baeuerle PA; Bommert K; Karawajew L; Dörken B; Bargou RC
    Leukemia; 2003 May; 17(5):900-9. PubMed ID: 12750704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.